Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | HTR2C | P28335 | 3/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | PLAT | P00750 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | UBE2N | P61088 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL311619 | 0.81 | MKNK1 (0.54) | HTR2CHTR2AHTR2BPLAT | |
| SCHEMBL27776218 | 0.81 | HTR3A (0.46) | KMT2AHTR2CHTR2AHTR2BKDM1A | |
| SCHEMBL6166041 | 0.81 | SLC18A3 (0.47) | KMT2AMEN1HTR2CHTR2A | |
| SCHEMBL312409 | 0.81 | SLC18A3 (0.50) | KMT2AMEN1HTR2CHTR2A | |
| Hydrochloric Acid SCHEMBL6806273 | 0.80 | SLC18A3 (0.46) | KMT2AMEN1HTR2CHTR2A | |
| Hydrochloric Acid SCHEMBL15732595 | 0.80 | HTR3A (0.45) | KMT2AHTR2CHTR2AHTR2BKDM1A | |
| Hydrochloric Acid SCHEMBL311386 | 0.80 | SLC18A3 (0.49) | KMT2AMEN1HTR2CHTR2A | |
| Hydrochloric Acid SCHEMBL1653372 | 0.80 | SLC18A3 (0.49) | KMT2AMEN1HTR2CHTR2A | |
| SCHEMBL311507 | 0.79 | HTR2A (0.43) | HTR2CHTR2AHTR2BPLATKDM4E | |
| SCHEMBL6168935 | 0.79 | HTR2B (0.48) | KMT2AMEN1HTR2BKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1349850-B1 | SODIUM CHANNEL MODULATORS DERIVED FROM 2-PIPERIDYLIMIDAZOLES | SOD CONSEILS RECH APPLIC (FR) | 2005-09-07 | — | — | EP | claimed |
| EP-1349850-A1 | SODIUM CHANNEL MODULATORS DERIVED FROM 2-PIPERIDYLIMIDAZOLES | Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) (FR) | 2003-10-08 | — | — | EP | claimed |
| WO-2002053559-A1 | SODIUM CHANNEL MODULATORS DERIVED FROM 2-PIPERIDYLIMIDAZOLES | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2002-07-11 | — | — | WO | claimed |
| US-20120071490-A1 | P70 S6 KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2012-03-22 | — | — | US | disclosed |
| US-8093383-B2 | P70 S6 kinase inhibitors | ELI LILLY AND COMPANY (US) | 2012-01-10 | — | — | US | disclosed |
| EP-2148880-A1 | P70 S6 KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2010-02-03 | — | — | EP | disclosed |
| US-20090163714-A1 | P70 S6 KINASE INHIBITORS | ELI LILLY AND COMPANY | 2009-06-25 | — | — | US | disclosed |
| WO-2008140947-A1 | P70 S6 KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2008-11-20 | — | — | WO | disclosed |
| US-20040077640-A1 | Sodium channel modulators derived from 2-piperidylimidazoles | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2004-04-22 | — | — | US | disclosed |
| EP-1349850-A1 | SODIUM CHANNEL MODULATORS DERIVED FROM 2-PIPERIDYLIMIDAZOLES | Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) (FR) | 2003-10-08 | — | — | EP | disclosed |
| WO-2002053559-A1 | SODIUM CHANNEL MODULATORS DERIVED FROM 2-PIPERIDYLIMIDAZOLES | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2002-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077640-A1 | Sodium channel modulators derived from 2-piperidylimidazoles | KCNH1, HCN4, KCNH2 | KMT2A 3010/4885MEN1 4835/4885HTR2C 652/4885 |
| US-20090163714-A1 | P70 S6 KINASE INHIBITORS | RPS6KA6, RPS6KA1, RPS6KA2 | KMT2A 3302/4885MEN1 3248/4885HTR2C 3714/4885 |
| US-20120071490-A1 | P70 S6 KINASE INHIBITORS | RPS6KA6, RPS6KA1, RPS6KA2 | KMT2A 3302/4885MEN1 3248/4885HTR2C 3714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.